The TBCRC049 Trial for Treating Leptomeningeal Metastases in HER2+ Breast Cancer

December 14, 2019
Adam M. Brufsky, MD, PhD, FACP

Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.